Nathaniel Lacktman, Jacqueline Acosta Author Article on How Telemedicine Startups Can Survive Amid Renewed Regulation
24 January 2022
Foley & Lardner LLP Partner Nathaniel Lacktman and Special Counsel Jacqueline Acosta wrote an article, “Telemedicine Startups Can Survive and Thrive Under Renewed Regulation,” for TechCrunch, an online newspaper focusing on high-tech and startup companies. The piece discusses how and why telemedicine companies should research and understand the varied patchwork of state and federal regulations, analyze them to identify patterns, and build scalable business models.
Lacktman and Acosta say that “the pressure for some form of regulatory clarity is only likely to increase” and “no market participant should be lulled into inaction by temporary extensions of crisis waivers.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”